MedTrace Logo

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

NCT04483414 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-05-19

No results posted yet for this study

Summary

The goal of this research is to examine the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to detect sites of recurrent prostate cancer in patients with biochemical recurrence previously treated with radical prostatectomy (RP) or external beam radiation (EBRT) and to assess treatment response to subsequent salvage therapy.

Conditions

  • Prostate Cancer
  • Prostate Cancer Metastatic
  • Prostate Cancer Metastatic to Bone

Interventions

DRUG

68Ga PSMA-11 injection

Injection of 68Ga PSMA-11

PROCEDURE

Positron Emission Tomography/Computed Tomography

PET/CT scan after 68Ga PSMA-11 injection

Sponsors & Collaborators

  • Dana Mathews

    lead OTHER

Principal Investigators

  • Orhan K Oz, MD, PhD · UT Southwestern Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2023-04-05
Completion
2023-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483414 on ClinicalTrials.gov